Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088829 · ClinicalTrials.gov registry record · Phase 2
Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer
A Phase 2 study, sponsored by Georgetown University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT00088829 is a Phase 2 study that was terminated before completion, run by Georgetown University. The registered enrollment target is 22 participants.
The verdict
NCT00088829, a Phase 2 study, was terminated before completion, sponsored by Georgetown University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
RATIONALE: Analyzing genes for changes before and after chemotherapy may help doctors predict a patient's response to treatment and help plan the most effective treatment. PURPOSE: This clinical trial is studying how well genetic testing works in predicting response to paclitaxel in women who have unresected breast cancer.
Interventions
- GENETIC microarray analysis
- DRUG Paclitaxel
- PROCEDURE biopsy
- DRUG paclitaxel
- PROCEDURE neoadjuvant therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2001-04 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00088829
The ClinicalTrials.gov registry entry for NCT00088829 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which microarray analysis is the first listed.
NCT00088829 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00088829 about?
NCT00088829 is a clinical study titled "Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer". RATIONALE: Analyzing genes for changes before and after chemotherapy may help doctors predict a patient's response to treatment and help plan the most effective treatment. PURPOSE: This clinical trial is studying how well genetic testing works in predicting response to paclitaxel in women who have ...
What is the current status of trial NCT00088829?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2001-04. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00088829?
The interventions under investigation include: microarray analysis (GENETIC), Paclitaxel (DRUG), biopsy (PROCEDURE), paclitaxel (DRUG), neoadjuvant therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00088829?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.